News
April 25, 2024
Inhalon Biopharma to Share Progress on Inhaled Monoclonal Antibody Therapy at 9th Annual Inhalation and Respiratory Drug Delivery Congress Read More
March 20, 2024
Inhalon Biopharma Announces Positive Results from Study Demonstrating Superior Safety and Efficacy of its Inhaled Antibody Platform Over Systemic Dosing Read More
March 14, 2024
Inhalon Biopharma Announces Two Publications Advancing its Inhaled Antibody Treatment Platform for Acute Respiratory Infections Read More
January 8, 2024
Inhalon Biopharma to Present on Product Development Pipeline at Biotech Showcase Read More
November 15, 2023
Inhalon Biopharma Secures U.S. Army Medical Research and Development Command Award to Support Development of Inhaled Therapeutics for Treatment of COVID-19 Read More
November 1, 2023
Inhalon Biopharma Expands Therapeutic Horizons with Licensing of hMPV Antibodies from the University of Georgia Read More
October 6, 2023
Inhalon Biopharma to Share Progress in Development of Inhaled Antibody Platform at the Bio Investor Forum and Bio Europe Read More
June 30, 2022
Inhalon Biopharma Closes Series A Financing to Further their Study of Inhaled Antibodies Read More
October 7, 2021
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN‑006 to Treat COVID-19 Read More
July 22, 2021
Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home Read More
July 16, 2021
Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer Read More
May 26, 2021
Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled “Muco-trapping” Antibody for the Treatment of COVID-19 Read More